Epilepsy Trial, Recruiting (NCT07110454)

Epilepsy Trial, Recruiting NCT07110454 Sponsor: Epiminder America, Inc. Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT07110454 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have already taken part in the DETECT study and met all of its requirements to join that study
You must have received a small implanted device called the "Minder device" as part of the DETECT study
You must have finished the DETECT study, either because an important health event was detected or because you completed the full 6-month follow-up visit
You must still have the Minder device implanted in your body
You must still meet the same health requirements that allowed you to join the original DETECT study (confirm with trial site)

Who may not be able to join:

You may not be eligible if you now meet any of the reasons that would have stopped you from joining the original DETECT study
You may not be eligible if you need medical treatments or scans that cannot safely be used alongside the Minder device, such as an MRI (magnetic resonance imaging) scan — a type of detailed body scan that uses magnets

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-717-3185

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07110454

Sponsor: Epiminder America, Inc.

Phase: Not Applicable

Status: Recruiting

Condition: Epilepsy

Trial contact: 800-717-3185

More information: https://clinicaltrials.gov/study/NCT07110454

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have already taken part in the DETECT study and met all of its requirements to join that study
You must have received a small implanted device called the "Minder device" as part of the DETECT study
You must have finished the DETECT study, either because an important health event was detected or because you completed the full 6-month follow-up visit
You must still have the Minder device implanted in your body
You must still meet the same health requirements that allowed you to join the original DETECT study (confirm with trial site)

Who may not be able to join:

You may not be eligible if you now meet any of the reasons that would have stopped you from joining the original DETECT study
You may not be eligible if you need medical treatments or scans that cannot safely be used alongside the Minder device, such as an MRI (magnetic resonance imaging) scan — a type of detailed body scan that uses magnets

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Epiminder America, Inc.

Registry

ClinicalTrials.gov

Start date

1 June 2026

Est. completion

1 January 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate the Minder System to aid in treatment following an actionable event by comparing change using the Patient Global Impression scale (PGIC) from baseline to follow-up.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov